cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Evaluation of Circulating DNA as a Biomarker of Residual Disease After Chemoradiotherapy for Locally Advanced Head and Necksquamous Cell Carcinoma

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.

The main question it aims to answer is :

- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).

Participants will :

• be included in the main study (Neck-TAR)
• have a blood sample 1 and 3-month after the end of treatment

Selection Criteria:

• Patient included in NeckTAR study
• Written informed consent signed for NeckTAR-IN study
• Affiliation to the French social security system